JP2024507367A5 - - Google Patents
Info
- Publication number
- JP2024507367A5 JP2024507367A5 JP2023550610A JP2023550610A JP2024507367A5 JP 2024507367 A5 JP2024507367 A5 JP 2024507367A5 JP 2023550610 A JP2023550610 A JP 2023550610A JP 2023550610 A JP2023550610 A JP 2023550610A JP 2024507367 A5 JP2024507367 A5 JP 2024507367A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- period
- pharmaceutical composition
- oral pharmaceutical
- chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163153095P | 2021-02-24 | 2021-02-24 | |
| US63/153,095 | 2021-02-24 | ||
| US202163213998P | 2021-06-23 | 2021-06-23 | |
| US63/213,998 | 2021-06-23 | ||
| PCT/US2022/017485 WO2022182733A1 (en) | 2021-02-24 | 2022-02-23 | Methods for treating disorders ameliorated by muscarinic receptor activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507367A JP2024507367A (ja) | 2024-02-19 |
| JP2024507367A5 true JP2024507367A5 (https=) | 2025-03-03 |
Family
ID=83048440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023550610A Pending JP2024507367A (ja) | 2021-02-24 | 2022-02-23 | ムスカリン受容体活性化によって改善される障害を処置するための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240156802A1 (https=) |
| EP (1) | EP4297732A4 (https=) |
| JP (1) | JP2024507367A (https=) |
| AU (1) | AU2022226157A1 (https=) |
| BR (1) | BR112023017019A2 (https=) |
| CA (1) | CA3209262A1 (https=) |
| IL (1) | IL305412A (https=) |
| TW (1) | TW202332443A (https=) |
| WO (1) | WO2022182733A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102408292B1 (ko) | 2018-09-28 | 2022-06-10 | 카루나 세러퓨틱스 인코포레이티드 | 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법 |
| EP4091607A1 (en) * | 2021-05-18 | 2022-11-23 | Karuna Therapeutics, Inc. | Methods for treating central nervous system disorders with muscarinic receptor activator xanomeline and antipsychotics |
| US12269818B2 (en) | 2023-04-24 | 2025-04-08 | Terran Biosciences Inc. | Analogs of xanomeline |
| WO2026064593A1 (en) * | 2024-09-20 | 2026-03-26 | Karuna Therapeutics, Inc. | Method and compositions relating to the treatment of neuro-degenerative and psychiatric diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010540454A (ja) * | 2007-09-21 | 2010-12-24 | アカディア ファーマシューティカルズ，インコーポレーテッド | ピマバンセリンと他の薬剤との併用投与 |
| KR102408292B1 (ko) * | 2018-09-28 | 2022-06-10 | 카루나 세러퓨틱스 인코포레이티드 | 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법 |
| CN120514706A (zh) * | 2019-11-18 | 2025-08-22 | 卡鲁娜治疗学有限公司 | 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法 |
| US20220370454A1 (en) * | 2021-05-18 | 2022-11-24 | Karuna Therapeutics, Inc. | Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics |
-
2022
- 2022-02-23 JP JP2023550610A patent/JP2024507367A/ja active Pending
- 2022-02-23 BR BR112023017019A patent/BR112023017019A2/pt unknown
- 2022-02-23 WO PCT/US2022/017485 patent/WO2022182733A1/en not_active Ceased
- 2022-02-23 CA CA3209262A patent/CA3209262A1/en active Pending
- 2022-02-23 IL IL305412A patent/IL305412A/en unknown
- 2022-02-23 EP EP22760321.4A patent/EP4297732A4/en active Pending
- 2022-02-23 AU AU2022226157A patent/AU2022226157A1/en active Pending
- 2022-02-24 TW TW111106823A patent/TW202332443A/zh unknown
-
2023
- 2023-08-23 US US18/454,177 patent/US20240156802A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024507367A5 (https=) | ||
| ES3029536T3 (en) | Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2019503365A5 (https=) | ||
| JP2005515964A5 (https=) | ||
| TW200815048A (en) | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies | |
| JP2021512906A5 (https=) | ||
| ES3060114T3 (https=) | ||
| JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP2022532766A5 (https=) | ||
| JP2022521233A5 (https=) | ||
| RU2004131214A (ru) | Способы лечения когнитивных расстройств | |
| JP2004525940A (ja) | 火照りの処置のためのデュロキセチン | |
| JP2023548429A5 (https=) | ||
| JP2023522415A5 (https=) | ||
| JP2020517670A (ja) | うつ病を治療するための組成物および方法 | |
| JP2004091473A (ja) | 色素沈着改善治療薬 | |
| JP2023531930A5 (https=) | ||
| JP2024506385A5 (https=) | ||
| TW200918094A (en) | Pharmaceutical acceptable composition containing non-steroidal anti-inflammatory drug and local anesthetics | |
| de Queiroz et al. | Dental care management of a young patient with extensive lymphangioma of the tongue: a case report | |
| WO2004017973A1 (ja) | 統合失調症治療剤 | |
| WO2024078468A1 (zh) | 二苯乙烯衍生物用于预防和或治疗溃疡的用途 | |
| JP2024531799A5 (https=) | ||
| JP2008535907A5 (https=) |